Month: May 2020

Highlights include $22 million public offering, uplisting to Nasdaq, Pivotal RegistrationTrial enrollment completed, and Pivotal Registration Topline Data Expected in 2020NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial results for the quarter ended March 31, 2020.HighlightsCompleted $22.0 million public offeringUplisted to the Nasdaq Capital MarketCompleted enrollment of our Registration Pivotal Trial (FOCUS) investigating Melphalan/HDS in the treatment of patients with unresectable hepatic-dominant ocular melanoma (mOM)Elizabeth Czerepak, Steven Salamon and Gilad Aharon joined our board of directorsMilestone ExpectationsTopline data from FOCUS registration trial expected...

CAMBRIDGE, Mass. and BERLIN and ROSTOCK, Germany, May 15, 2020 (GLOBE NEWSWIRE) — Centogene N.V (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that Mr. Oved Amitay will be stepping down as Chief Business Officer (“CBO”) and leaving the Company effective May 31, 2020. He will be succeeded by Mr. Sun Kim, our current Chief Strategy and IR Officer, who will assume Mr. Amitay’s responsibilities as CBO until a permanent CBO has been appointed.  Mr. Amitay will continue his work for rare diseases patients in the non-profit sector, where he will serve as Chief Executive Officer of a patient advocacy organization. Prof. Arndt Rolfs, CEO of the Company, stated, “We...

MONTRÉAL, May 15, 2020 (GLOBE NEWSWIRE) — With the approval of the Superior Court of Québec, Nemaska Lithium Inc. (the “Corporation“) proceeded yesterday with the sale of all its 15,849,455 common shares of Monarch Gold Corporation (“Monarques”). The shares were sold at an average price of $0.225, for a total amount of approximately $3.5 million. These shares were not subject to any security and their sale has enabled the Corporation to generate additional liquidity for the ongoing restructuring process under the Companies’ Creditors Arrangement Act (CCAA).More information regarding the Corporation’s situation, decisions or actions will continue to be provided on an ongoing basis, as required by applicable law or as may be determined by the Corporation or the Court. For more information, visit www.nemaskalithium.com. You can also...

MONTRÉAL, 15 mai 2020 (GLOBE NEWSWIRE) — Avec l’approbation de la Cour supérieure du Québec, Nemaska Lithium Inc. (la « Société ») a procédé hier à la vente en totalité de ses 15 849 455 actions ordinaires de Corporation Aurifère Monarques (« Monarques »). Les actions ont été vendues à un prix moyen de 0,225 $, pour une valeur totale d’approximativement 3,5 millions $. Ces actions n’étaient grevées par aucune sûreté, et leur vente a permis à la Société de générer des liquidités supplémentaires dans le cadre du processus de restructuration en cours sous l’autorité de la Loi sur les arrangements avec les créanciers des compagnies (LACC).De plus amples informations concernant la situation, les décisions ou les actions de la Société continueront à être fournies de façon continue, conformément à la législation ou si la Société ou la...

BARRIE, Ontario, May 15, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that its subsidiary, MediPharm Labs Australia Pty. Ltd. (“MediPharm Labs Australia”) has secured its first European white-label cannabis supply agreement with Therismos Limited (“Therismos”), a subsidiary of Cannaray Limited (“Cannaray”).Under the three-year agreement, MediPharm Labs Australia will supply a range of cannabis oil products that meet the high-quality standards set by the German Institute for Drugs and Medical Devices that requires all medicinal cannabis products be manufactured under Good Manufacturing Practices (“GMP”).Cannaray,...

VANCOUVER, Washington, May 15, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced it is offering comprehensive cytokine profiling (including RANTES levels) through its diagnostic partner company, IncellDx, to help physicians understand the pathogenesis of Childhood Inflammatory Disease Related to COVID-19. These laboratory tests are exploratory in nature and not intended for clinical decision making.Recent reports in parts of the U.S. and Europe suggest a rare and potentially fatal inflammatory disease linked to the novel coronavirus is afflicting a small number of children. The condition resembles a rare childhood illness called Kawasaki disease,...

First Primary Outcome Measure Met with All Eight Patients Achieving Hematologic EngraftmentImproved Motor Skills, Stable Cognitive Scores and Normal Growth Seen in First Two PatientsOne-year Follow-up Results and Initiation of Registrational Trial Expected in 2021BOSTON and LONDON, May 15, 2020 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced new interim data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, an ex vivo autologous hematopoietic stem cell (HSC) gene therapy in development for the treatment of mucopolysaccharidosis type I (MPS-I) at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy. The results are being shared virtually in two presentations at the American Society of Gene & Cell Therapy (ASGCT)...

SUWANEE, Ga., May 15, 2020 (GLOBE NEWSWIRE) — Digirad Corporation (Nasdaq: DRAD; DRADP) (“Digirad” or the “Company”) reported today its financial results for the first quarter (Q1) ended March 31, 2020.Q1 2020 Financial Highlights vs. Q1 2019 *Total revenue increased to $28.9 million from $23.9 millionGross profit increased to $4.4 million from $4.0 millionNet loss was $3.0 million compared to a net loss of $1.7 millionNon-GAAP adjusted EBITDA from continuing operations decreased to $0.5 million from $0.8 millionNon-GAAP free cash flow of $0.6 million versus $(2.1) million* Since September 10, 2019, Digirad has been operating as a diversified holding company (“HoldCo”) with three business divisions: Healthcare, Building & Construction, and Real Estate & Investments. Digirad’s Q1 2020 results include financial and operational...

BETHLEHEM, Pa., May 15, 2020 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the UBS Virtual Global Healthcare Conference.  The conference will be simultaneously webcast over the Internet.Dr. Tang is scheduled to speak on May 20, 2020, at approximately 10:50 AM Eastern Standard Time (7:50 AM Pacific Time).  Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, www.orasure.com and clicking on the Investor Info link.  A replay of the webcast will be available on OraSure Technologies’ web site for seven days.  Alternatively, you can access the live webcast of the presentation via the...

MIAMI BEACH, Fla., May 15, 2020 (GLOBE NEWSWIRE) — Gratitude Health, Inc. (OTCQB: GRTD) (the “Company”) today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 with the Securities and Exchange Commission on May 14, 2020 (the “Annual Report”).            The consolidated financial statements contained in the Annual Report consist of the consolidated balance sheets of the Company as of December 31, 2019 and 2018, and the related consolidated statements of operations, consolidated statements of changes in stockholders’ equity (deficit), and consolidated statements of cash flows for the years ended December 31, 2019 and 2018, and related notes, and accordingly do not reflect the acquisition of our new wholly-owned subsidiary, Home Bistro, which was consummated on April 20, 2020, as more...